PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19706768-4 2009 ANOVA and regression were performed to assess relationships among the frequency and spectra of HPRT mutations with disease, duration of illness, duration of treatment, and total therapeutic dose of azathioprine and 6-MP. Azathioprine 198-210 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 95-99 11707060-13 2001 Both mercaptopurine and its prodrug azathioprine are metabolised to active compounds (6-thioguanine nucleotides; 6-TGN) by hypoxanthine-guanine phosphoribosyltransferase and to inactive metabolites by the polymorphically expressed thiopurine S-methyltransferase (TPMT) and xanthine oxidase. Azathioprine 36-48 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 123-169 16107271-1 2005 Many patients undergoing chronic therapy with the purine analogue Azathioprine (Aza) have highly elevated HPRT lymphocyte mutant frequencies (MFs), and it is likely that these increases are due to selection of pre-existing HPRT mutant lymphocytes. Azathioprine 66-78 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 106-110 16107271-1 2005 Many patients undergoing chronic therapy with the purine analogue Azathioprine (Aza) have highly elevated HPRT lymphocyte mutant frequencies (MFs), and it is likely that these increases are due to selection of pre-existing HPRT mutant lymphocytes. Azathioprine 66-78 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 223-227 16107271-1 2005 Many patients undergoing chronic therapy with the purine analogue Azathioprine (Aza) have highly elevated HPRT lymphocyte mutant frequencies (MFs), and it is likely that these increases are due to selection of pre-existing HPRT mutant lymphocytes. Azathioprine 66-69 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 106-110 16107271-1 2005 Many patients undergoing chronic therapy with the purine analogue Azathioprine (Aza) have highly elevated HPRT lymphocyte mutant frequencies (MFs), and it is likely that these increases are due to selection of pre-existing HPRT mutant lymphocytes. Azathioprine 66-69 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 223-227 16107271-11 2005 The data suggest that mice chronically treated with 5 and 10mg/kg Aza (doses similar to those used in humans) have elevated Hprt MFs due to clonal amplification of selected Hprt mutants. Azathioprine 66-69 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 124-128 16107271-11 2005 The data suggest that mice chronically treated with 5 and 10mg/kg Aza (doses similar to those used in humans) have elevated Hprt MFs due to clonal amplification of selected Hprt mutants. Azathioprine 66-69 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 173-177 18008354-2 2007 Extremely high HPRT lymphocyte mutant frequencies (MFs) are found in humans and mice chronically treated with Aza, and these elevated MFs appear to be caused by selection and amplification of pre-existing HPRT mutant lymphocytes. Azathioprine 110-113 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 15-19 16695929-3 1967 This inability to respond to azathioprine can be directly related to the absence in these patients of the enzyme hypoxanthine-guanine phosphoribosyltransferase which is required for conversion of the drug or its metabolites to the biochemically active ribonucleotide form. Azathioprine 29-41 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 113-159 10849375-3 2000 Mutations of the hypoxanthine guanine phosphoribosyltransferase (hprt) gene measured by 6-thioguanine (TG) selection were studied in 28 patients (60 determinations) enrolled in a prospective double-blinded placebo-controlled study of azathioprine immunosuppression: 17 patients (34 determinations) were receiving azathioprine and 11 (26 determinations) placebo. Azathioprine 234-246 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 17-63 10849375-3 2000 Mutations of the hypoxanthine guanine phosphoribosyltransferase (hprt) gene measured by 6-thioguanine (TG) selection were studied in 28 patients (60 determinations) enrolled in a prospective double-blinded placebo-controlled study of azathioprine immunosuppression: 17 patients (34 determinations) were receiving azathioprine and 11 (26 determinations) placebo. Azathioprine 234-246 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 65-69 10849375-3 2000 Mutations of the hypoxanthine guanine phosphoribosyltransferase (hprt) gene measured by 6-thioguanine (TG) selection were studied in 28 patients (60 determinations) enrolled in a prospective double-blinded placebo-controlled study of azathioprine immunosuppression: 17 patients (34 determinations) were receiving azathioprine and 11 (26 determinations) placebo. Azathioprine 313-325 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 17-63 10849375-3 2000 Mutations of the hypoxanthine guanine phosphoribosyltransferase (hprt) gene measured by 6-thioguanine (TG) selection were studied in 28 patients (60 determinations) enrolled in a prospective double-blinded placebo-controlled study of azathioprine immunosuppression: 17 patients (34 determinations) were receiving azathioprine and 11 (26 determinations) placebo. Azathioprine 313-325 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 65-69 10849375-6 2000 However, azathioprine, which is converted to 6-mercaptopurine in vivo, selects and amplifies the hprt mutants that do arise. Azathioprine 9-21 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 97-101 10849375-7 2000 Clinical azathioprine resistance may be explained by hprt mutations arising in T cells relevant to the underlying autoimmune process. Azathioprine 9-21 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 53-57 1585469-1 1992 The immunosuppressive efficacy of azathioprine is related to its rapid metabolism in vivo to 6-mercaptopurine (6MP), with subsequent conversion to thioguanine nucleotides by an anabolic route involving hypoxanthine-guanine phosphoribosyltransferase. Azathioprine 34-46 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 202-248 6540565-0 1984 Hypoxanthine-guanine phosphoribosyltransferase-independent toxicity of azathioprine in human lymphoblasts. Azathioprine 71-83 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 0-46 2934083-3 1985 When both stimulator and responder lymphocytes in the MLR were HGPRT deficient, azathioprine (36 microM) was much more inhibitory than 6-MP (100 microM). Azathioprine 80-92 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 63-68 2934083-5 1985 The difference in inhibitory activity between azathioprine and 6-MP was reduced when normal stimulator lymphocytes were cultured with HGPRT deficient responder lymphocytes in the MLR. Azathioprine 46-58 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 134-139 33929082-1 2021 Xanthine oxidase (XO) competes with thiopurine S-methyltransferase (TPMT) and hypoxanthine guanine phosphoribosyltransferase (HPRT) to metabolize azathioprine (AZA)/6-mercaptopurine (6-MP) in vivo. Azathioprine 146-158 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 78-124 33929082-1 2021 Xanthine oxidase (XO) competes with thiopurine S-methyltransferase (TPMT) and hypoxanthine guanine phosphoribosyltransferase (HPRT) to metabolize azathioprine (AZA)/6-mercaptopurine (6-MP) in vivo. Azathioprine 146-158 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 126-130 33929082-1 2021 Xanthine oxidase (XO) competes with thiopurine S-methyltransferase (TPMT) and hypoxanthine guanine phosphoribosyltransferase (HPRT) to metabolize azathioprine (AZA)/6-mercaptopurine (6-MP) in vivo. Azathioprine 160-163 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 78-124 33929082-1 2021 Xanthine oxidase (XO) competes with thiopurine S-methyltransferase (TPMT) and hypoxanthine guanine phosphoribosyltransferase (HPRT) to metabolize azathioprine (AZA)/6-mercaptopurine (6-MP) in vivo. Azathioprine 160-163 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 126-130